CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Who Benefits From Zero Based Budgeting highlights common situations where this method shines, including clarity, control, and goal attainment.
18,389 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Alphabet surged over the past year, but a 10% pullback from its high has investors wondering if now is the moment to ...
Investors are debating whether removing the weakest members of the S&P 500 improves long-term results. Here's what th...
Early data from U.S. host cities show a modest but tangible lift in tourism and employment during the tournament wind...
If you're worried about market crash? you're not alone. This guide explains how investing in three reliable dividend ...
Oil markets often move on how tight or loose inventories look. This guide explains why companies sounding alarm inven...
A high-profile tragedy underscores why solid financial planning matters. This guide translates that lesson into actio...
San Francisco-based Peregrine Technologies locked in a $250 million Series D as it readies its platform for the 2026 ...
When the AI rally paused, investors turned to dependable dividend names. Johnson Johnson, Altria, and Verizon led gai...
A statewide pattern shows elder fraud couriers siphoning millions from dozens of seniors. This guide explains how the...
Toast is reshaping restaurant tech with a modular growth approach that blends software, payments, and services. This ...
Strong cloud demand and AI-driven spending helped lift amazon and alphabet today, putting the spotlight on the broade...